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Clinical, epidemiological, and experimental evidence indicate that the insulin-like growth 
factors (IGFs) are important mediators in the biochemical chain of events that lead from 
a phenotypically normal to a neoplastic cell. The IGF1 receptor (IGF1R), which mediates 
the biological actions of IGF1 and IGF2, exhibits potent pro-survival and antiapoptotic 
activities. The IGF1R is highly expressed in most types of cancer and is regarded as a 
promising therapeutic target in oncology. p53 is a transcription factor with tumor sup-
pressor activity that is usually activated in response to DNA damage and other forms 
of cellular stress. On the basis of its protective activities, p53 is commonly regarded as 
the guardian of the genome. We provide evidence that the IGF signaling axis and p53 
genome protection pathways are tightly interconnected. Wild-type, but not mutant, p53 
suppresses IGF1R gene transcription, leading to abrogation of the IGF signaling net-
work, with ensuing cell cycle arrest. Gain-of-function, or loss-of-function, mutations of 
p53 in tumor cells may disrupt its inhibitory activity, thus generating oncogenic molecules 
capable of transactivating the IGF1R gene. The interplay between the IGF1 and p53 
pathways is also of major relevance in terms of metabolic regulation, including glucose 
transport and glycolysis. A better understanding of the complex physical and functional 
interactions between these important signaling pathways will have major basic and 
translational relevance.
Keywords: insulin-like growth factor 1, iGF1 receptor, tumor suppressors, p53, BRCA1, transcription regulation, 
genome protection
THe iNSULiN-LiKe GROwTH FACTOR NeTwORK: 
LiGANDS, ReCePTORS, AND BiNDiNG PROTeiNS
The processes of growth, development, and cell death are tightly regulated by multiple cellular 
and secreted factors that, in a highly orchestrated fashion, control the stage- and tissue-specific 
expression of a wide array of genes. Disruption of this finely tuned genetic program may lead to 
a pathological phenotype, including tumor formation. Modern biological research is aimed at 
dissecting physiological and pathological processes at defined levels of regulation and tackling 
biological questions in a comprehensive and integrated manner.
The insulin-like growth factors (IGF1 and IGF2) are a family of mitogenic peptides with 
important roles in diverse aspects of body function (1). The mature circulating IGF1 and IGF2 
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FiGURe 1 | Schematic representation of iGF network components. The IGF system is comprised of three ligands (insulin, IGF1, and IGF2), three typical 
cell-surface receptors [insulin receptor (INSR), IGF1 receptor (IGF1R), and IGF2 receptor (IGF2R)], and at least six IGF-binding proteins (IGFBP1–6). The INSR has 
two isoforms, INSR-A and INSR-B, which differ in the absence or presence, respectively, of exon 11-encoded sequences. In addition to the typical receptors, 
naturally occurring hybrid receptors have been described in which an α/β INSR hemi-receptor is linked to an α/β IGF1R hemi-receptor. The IGF2R is a single-chain 
polypeptide composed of 15 repeat sequences and a short cytoplasmic domain. The IGF2R is homologous to the mannose 6-phosphate receptor and is involved in 
the recycling of lysosomal enzymes. IGFBP3 is the most abundant IGFBP in serum, and it is usually present as a ternary complex that includes the ligand and an 
acid-labile subunit (ALS). IGF bioavailability is also modulated by IGFBP proteases that cleave IGFBPs in a tissue-specific manner.
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contain, respectively, 70 and 67 amino acids and display a 
marked similarity to proinsulin. Both peptides contain A and B 
domains, analogous to the A and B chains of insulin. However, 
unlike insulin, IGF1 and IGF2 retain the C-peptide, which is 
absent in the mature insulin molecule. For more than 50 years, 
the IGFs have attracted enormous scientific and clinical interest. 
This broad attention emanates from the appreciation that IGFs 
mediate fundamental biological processes at multiple ontogenetic 
stages (e.g., embryonic, infancy, adolescence, adulthood) and at 
virtually every level of organization (e.g., cells, tissues, organs, 
organisms) (2–5).
Insulin-like growth factors were originally identified as 
liver-secreted hormones, primarily involved in mediating the 
endocrine actions of growth hormone (GH, somatotropin) (6). 
Appropriately, the term somatomedin was initially adopted. 
Subsequently, the IGFs were conclusively demonstrated to be 
synthesized by most extrahepatic organs, sites in which they 
exhibit autocrine and paracrine modes of action. As explained 
in the next section, IGF1 is a progression factor that is needed 
to advance throughout the various phases of the cell cycle. The 
biological actions of IGF1 and IGF2 are mediated via activation 
of the IGF1 receptor (IGF1R), a transmembrane heterotetramer 
whose cytoplasmic tyrosine kinase domain is linked to the 
ras–raf–MAPK and PI3K–PKB/Akt signal transduction cascades 
(7–9). The IGF1R exhibits marked structural and functional 
homology to the insulin receptor (INSR), a finding that reflects 
a common evolutionary origin (10). The divergent biological 
activities of INSR and IGF1R are described in the next section. 
Unlike insulin that circulates in a free form in serum, IGF1 and 
IGF2 are bound in the circulation and extracellular spaces to a 
family of IGF-binding proteins (IGFBP1–6). IGFBPs control the 
bioavailability of both IGFs by modulating their release, trans-
port, and degradation (11). The various components of the IGF 
network are illustrated in Figure 1.
iGFs PLAY KeY ROLeS iN HOMeOSTASiS 
ReGULATiON: PHYSiOLOGiCAL AND 
PATHOLOGiCAL ASPeCTS
The concept that INSR activation (mainly by insulin) leads 
primarily to metabolic activities while IGF1R activation (mainly 
by IGF1 or IGF2) leads to proliferative events was the prevalent 
dogma for more than 45 years (12, 13). These beliefs have been 
challenged in recent years due, in part, to the availability of 
transgenic and knockout animal models with organ-specific dis-
ruption or, alternatively, overexpression of IGF axis components. 
Whereas the general notion, in broad terms, is still regarded as 
correct, there is ample evidence in support of the view that INSR 
is also capable of mediating proliferative types of activities while, 
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on the other hand, IGF1R is responsible for specific metabolic 
actions (14–16).
The structural and functional homology between INSR and 
IGF1R suggest that both molecules are derived from a common 
ancestral precursor that probably participated in food intake 
and regulation of cellular growth (17). A divergence of func-
tions most likely occurred before the appearance of the first 
vertebrates (18). However, in view of their common evolution-
ary origins and semi-conserved architecture, there is a certain 
degree of cross talk between the insulin and IGF ligands and 
their receptors (19).
As mentioned above, IGF1 stimulates mitogenic responses and 
inhibits cell death in a wide variety of cell types (20). Quiescent 
cells in G0 can be induced to enter G1 by competence factors (e.g., 
PDGF, bFGF). Once the cell enters into G1, sub-physiological 
doses of IGF1 will allow the cell to evade arrest in G1 and to 
progress through the cell cycle (21), hence complying with the 
definition of progression factors (22). IGF1 exhibits a variety of 
cellular functions, including regulation of hormone synthesis and 
secretion, chemoattractant migration, immune cell recognition, 
and neuromodulation. Metabolic effects of IGF1 include, among 
others, elevation of glucose uptake and hypoglycemia, without 
lowering free fatty acid levels (1, 19). In addition, IGF1 improves 
renal function by increasing renal blood flow and glomerular 
filtration rate (23). The cardinal role of the IGF axis in growth 
and development was demonstrated by the severe growth deficits 
observed in mice in which components of the IGF system, each 
one individually and in combination, were disrupted by homolo-
gous recombination (24).
THe iGF1R: A POTeNT CeLL 
SURvivAL MeDiATOR
Clinical and experimental studies conducted since the early 
1980s have established that nearly all human tumors display 
augmented IGF1R concentrations (25, 26). Elevated receptor 
levels are correlated with enhanced IGF1 and IGF2 binding and 
amplified IGF1R activation (phosphorylation). However, the 
levels of expression of the IGF1R gene as a determinant of IGF 
action and, in particular, the pathological significance of IGF1R 
overexpression, are still open questions (27–32). The archetypal 
features of the IGF1R include the following.
[1] potent antiapoptotic and cell survival capacities;
[2] critical roles in invasion, metastasis, and angiogenesis;
[3] contribution to malignant transformation (4, 5).
Experimental corroboration in favor of a critical role for 
the IGF1R in oncogenesis was provided by studies showing 
that fibroblasts derived from IGF1R knockout mice, with a few 
exceptions, do not undergo transformation when exposed to 
cellular or viral oncogenes (33, 34). However, it is important to 
emphasize that IGF1R, per se, is not oncogenic. In other words, 
the ligand-activated receptor is unable to induce cellular trans-
formation. Furthermore, high IGF1R levels do not necessarily 
reflect the existence of a malignant phenotype. Thus, reduced 
circulating IGF1 values, such as those associated with congenital 
IGF1 deficiencies, usually lead to IGF1R upregulation. However, 
there is no evidence that these elevated IGF1R concentrations 
are correlated with a malignant phenotype (28). As mentioned 
above, IGF1 functions as a progression factor capable of “push-
ing” cells, including already transformed cells, through the cell 
cycle. Clinical and experimental data are consistent with the 
view that IGF1R expression and activation are fundamental pre-
requisites for acquisition of a malignant phenotype (10, 35). The 
converse scenario (i.e., that enhanced IGF1R gene expression in 
cancer is a consequence of the malignant phenotype) is, similarly, 
a biologically plausible theory that merits consideration. The 
molecular mechanisms responsible for the regulation of IGF1R 
gene expression are described in the next section.
TRANSCRiPTiONAL AND ePiGeNeTiC 
ReGULATiON OF THe IGF1R GeNe
Investigation of the IGF1R gene promoter is helping define the 
functional and physical foundations for transcriptional control 
of the gene. Comprehensive promoter analyses generated 
valuable information regarding cis-elements as well as trans-
acting factors that are responsible for IGF1R gene expression 
under physiological and pathological conditions. Transcription 
rate of the IGF1R gene is primarily dependent on a number 
of stimulatory nuclear proteins, including zinc-finger protein 
Sp1 (36, 37), E2F1 (38), Krüppel-like factor-6 (KLF6) (39), 
high-mobility group AT-hook (HMGA1) (40), etc. Some of 
these transcription factors directly bind specific cis-elements, 
including arrays of GC boxes located in the proximal IGF1R 
promoter region (i.e., protein–DNA interactions), whereas other 
nuclear proteins interact with members of the basal transcrip-
tion machinery (i.e., protein–protein interactions). Recent DNA 
affinity chromatography-based proteomic analyses using nuclear 
extracts of breast tumor cells along with biotin-labeled IGF1R 
promoter fragments, followed by mass spectroscopy, led to the 
identification of a large set of IGF1R promoter-binding transcrip-
tion factors (41). These transcription factors fall into a number 
of functional categories:
[1] cytoskeleton-associated proteins;
[2] proteins involved in transcription and regulation of nucleic 
acid metabolism;
[3] proteins involved in nuclear stability, chromatin structure, 
cell cycle, and gene expression;
[4] proteins involved in DNA repair, breaking, replication, and 
cell death;
[5] proteins involved in RNA splicing and processing, and 
translation.
Hence, Bioinformatic analyses suggest that the IGF1R gene 
plays key roles in multiple, seemingly unrelated, cellular pathways.
The interplay between steroid hormones and the IGF1 axis is 
of major clinical relevance in specific types of cancer, in particular 
adult epithelial tumors with a strong endocrine background 
(42–44). In this context, nuclear receptors, such as the estrogen 
(ER) and androgen (AR) receptors, were shown to stimulate 
IGF1R gene expression via mechanisms that involve ER and AR 
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binding to IGF1R promoter elements (45). On the other hand, 
mutant versions of AR were unable to enhance IGF1R promoter 
activity (46). Transcriptional regulation of the IGF1R gene by 
ER and AR is of major importance in the etiology of breast and 
prostate cancers, respectively (47, 48). In addition, the question 
whether DNA methylation is involved in epigenetic regulation of 
the IGF1R gene was recently investigated in a series of prostate 
cancer cell lines representing early or advanced (metastatic) 
stages of the disease. Results of methylation specific PCR, sodium 
bisulfite-direct DNA sequencing, and 5-Aza-2′-deoxycytidine 
experiments revealed that the IGF1R promoter is, most likely, 
not subject to DNA methylation at any stage of the disease (49).
Finally, a relevant question is whether genetic events might be 
linked to IGF1R overexpression in cancer. Most available clinical 
data support the notion that IGF1R gene mutations constitute a 
very rare event and no substantial evidence links IGF1R muta-
tions and cancer. In fact, heterozygous IGF1R mutations were 
reported in cases of intrauterine and postnatal growth restriction, 
but not in association with cancer (28, 50). Similarly, IGF1R gene 
amplification has been reported only in a small number of breast 
cancer and melanoma cases, suggesting that this genetic event is 
not a common mechanism in malignancy.
p53: A KeY PLAYeR iN GeNOMe 
iNTeGRiTY PROTeCTiON
p53 is a transcription factor with tumor suppressor activity that 
typically accumulates in the cell in response to DNA damage 
(51). In its hyperphosphorylated state, p53 is capable of arrest-
ing cell cycle progression at the G1 phase. Mutation of the p53 
tumor suppressor gene is the most common event in human 
cancer (52, 53). The p53 pathway is activated in response to a 
wide spectrum of cellular stress signals. These insults include 
DNA damage and telomere shortening, hypoxia, low nucleoside 
triphosphate pool sizes, spindle damage, heat and cold shock, 
inflammation and nitric oxide production, and, finally, activation 
of oncogenes by mutations (54, 55). These various strains bear 
the potential to decrease the fidelity of cell cycle progression 
and DNA replication, hence leading to increased mutation rates 
(56). Accumulation of mutations constitutes an early event in 
cellular transformation and may, eventually, lead to the establish-
ment of a cancerous phenotype. p53-mediated cell cycle arrest 
enables damaged DNA to be repaired before the replicative 
phase of the cell cycle (53, 57). Alternatively, p53 can elicit an 
apoptotic program. Based on these important protective roles, 
p53 is commonly regarded as the “guardian of the genome.” As 
described below, there is solid experimental and clinical data that 
suggest that p53 interacts with the IGF1 pathway at a number 
of levels, including (1) transcriptional regulation of IGF axis 
components, including the IGF1R gene; and (2) convergence 
of cytoplasmic and nuclear IGF1 and p53 signaling pathways. 
Finally, evidence assembled in recent years indicate that, in 
addition to its well-documented capacity to govern cell cycle 
progression, p53 activation also has a major impact on metabolic 
processes, including glucose transport (58) and obesity (59). This 
topic is described below.
DiFFeReNTiAL ReGULATiON OF 
IGF1R GeNe eXPReSSiON BY  
wiLD-TYPe AND MUTANT p53
The essential role of IGF1R in cell cycle progression and transfor-
mation led to the hypothesis that a potential mechanism by which 
the postmitotic, terminally differentiated cell kept out of the cell 
cycle may involve the constitutive inhibition of the IGF1R gene 
by wild-type forms of tumor suppressor genes (35). In accordance 
with this hypothesis, p53, the most frequently mutated tumor 
suppressor in human cancer, was identified as a bona fide nega-
tive regulator of the IGF1R gene. Cotransfection of a wild-type 
p53-encoding expression vector along with an IGF1R promoter 
luciferase reporter construct led to an ~90% suppression of IGF1R 
promoter activity (60, 61) (Figure 2). In contrast, tumor-derived 
mutant versions of p53-containing mutations at codons 143, 248, 
and 273 of the p53 molecule enhanced IGF1R promoter activity 
by 227, 319, and 406%, respectively.
Analyses aimed at defining the mechanistic basis of p53 regula-
tion of IGF1R gene expression included, among others, transcrip-
tion, mobility shift, and proteomic assays (41, 60, 61). Results 
of in  vitro transcription assays using purified GST-p53 protein 
established that the tumor suppressor abolished transcription of 
an IGF1R gene template in a dose-dependent fashion (Figure 2). 
In addition, mobility shift assays indicate that p53 seems to exert 
its effects via protein–protein interactions with members of the 
basal transcription machinery, including the TATA-binding pro-
tein (TBP). The question whether p53 can directly bind IGF1R 
promoter DNA sequences is still under investigation. Proteomic 
analyses showed p53 binding to the IGF1R promoter, however, 
it is still unclear whether the tumor suppressor is part of a large 
multimeric protein complex or, alternatively, whether it binds 
IGF1R DNA in a sequence-specific manner (41). Combined data 
indicate that the mechanism of action of wild-type p53 involves 
transcriptional suppression of the IGF1R gene. Gain-of-function, 
or loss-of-function, mutations of p53 in tumor cells seem to dis-
rupt its inhibitory activity, hence generating oncogenic molecules 
capable of transactivating the IGF1R gene. Because wild-type p53 
is a potent inducer of apoptosis, we assume that the effect of p53 
on apoptosis is mediated, at least in part, via suppression of the 
IGF1R promoter. Lack of IGF1R inhibition by mutant p53 mol-
ecules may help expand cancer cell populations that are otherwise 
destined to die (Figure 3).
Finally, wild-type p53 was also shown to inhibit transcription 
of the antiapoptotic IGF2 gene and to enhance transcription of 
the proapoptotic IGFBP3 (62, 63). Hence, tumor suppressor p53 
governs the activity of the entire IGF network by modulating in 
a coordinated fashion the expression of ligands, receptors, and 
binding proteins. A schematic representation of the interactions 
between the IGF axis and p53 is presented in Figure 4.
ReGULATiON OF IGF1R GeNe 
eXPReSSiON BY p53 HOMOLOGS
Studies have identified a family of proteins that are structur-
ally and functionally related to p53. Members of this family, 
FiGURe 2 | Differential regulation of iGF1R gene expression by wild-type and mutant p53. To evaluate the effect of p53 on IGF1R promoter activity, 
transient cotransfection experiments were performed in Saos-2 cells (an osteosarcoma cell line lacking endogenous p53) using a p53 expression vector along with 
an IGF1R promoter (nt −476 to +640) luciferase reporter construct (upper panel). Wild-type p53 suppressed IGF1R promoter activity in a dose-dependent manner, 
with maximal repression obtained with a dose of 2.5 μg DNA. Co-expression of tumor-derived mutant forms of p53 (bearing mutations at codons 143, 248, and 
273) along with an IGF1R promoter led to transcriptional stimulation of the IGF1R gene. In vitro transcription assays using the purified wild-type p53 along with an 
IGF1R promoter template indicate that the effect of p53 was indeed mediated at the level of transcription.
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specifically p63 and p73, retain the basic features of the p53 pro-
tein, including an acidic, N-terminal transactivation domain, a 
central DNA-binding domain, and a C-terminal oligomerization 
domain (64–66). In addition, p63 and p73 exhibit some of the 
biological properties of p53, including the ability to recognize and 
bind p53 target sequences, transactivate p53-responsive genes, 
and induce apoptosis. However, unlike p53, the genetic structures 
of p63 and p73 are extremely complex, leading to the synthesis 
of several isoforms. To investigate whether novel members of the 
p53 family share the paradigm of p53 suppression of the IGF1R 
gene, the regulation of IGF1R by p63 and p73 was evaluated 
in colon cancer cells. Results of coexpression studies using the 
IGF1R
IGFBP3
IGF1/2
p53Mdm2
IGF1
FiGURe 4 | Schematic representation of the interplay between the 
iGF1 signaling axis and p53 genome protection pathway. p53 is 
activated in response to a broad spectrum of cellular insults and, in its 
hyperphosphorylated state, it can lead to cell cycle arrest and/or apoptosis. 
p53 was shown to inhibit transcription of the antiapoptotic genes IGF2 and 
IGF1R. On the other hand, p53 enhanced expression of the proapoptotic 
gene IGFBP3. Thus, p53 is capable of regulating the activity of the entire IGF 
signaling axis by controlling expression and activity of ligands, receptors, and 
IGFBPs in a coordinated fashion. The abundance and activity of p53 itself 
was shown to be regulated by IGF1, which induced p53 degradation in an 
Mdm2-dependent fashion.
-
Normal Cell
Apoptosis
wt p53
Proliferation
+
Tumor Cell
ApoptosisProliferation
INR INR
mut p53
FiGURe 3 | impact of p53 status on cell proliferation and apoptosis. Under normal physiological conditions, activation of wild-type p53 following DNA 
damage, or other forms of cellular stress, may lead to stimulation or repression of various target genes. The IGF1R promoter has been identified as a bona fide 
target of p53. IGF1R transcription begins from a discrete promoter element termed initiator (INR). Transcriptional repression of IGF1R may lead to cell cycle arrest or, 
alternatively, increased apoptosis. p53 is the most frequently mutated gene in human cancer. Tumor cells containing mutant forms of p53 are typically expected to 
display large concentrations of IGF1R mRNA and cell-surface receptors. Increased IGF1 binding and IGF1R activation (phosphorylation) result in uncontrolled 
proliferation and/or abrogation of apoptosis, two critical traits of malignant cells.
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various p63 and p73 isoforms demonstrate that p63/p73 proteins 
suppressed IGF1R promoter activity in a dose-dependent man-
ner, suggesting an anti-oncogenic role for p53 homologs (67). 
On the other hand, mutant proteins were impaired in their ability 
to inhibit the IGF1R gene.
Although the multiplicity of p63/p73 isoforms precludes 
any generalization regarding their roles in cancer biology, 
it is evident that this family of p53 homologs is involved in 
acquisition and maintenance of a malignant phenotype (64, 65). 
As depicted above for p53, negative regulation of IGF1R by p63/
p73 leads to diminished IGF binding, a characteristic feature of 
terminally differentiated cells. On the other hand, disruption of 
p53/p63/p73 pathways in cancer cells may result in impaired 
suppression of IGF1R transcription, with enhanced binding 
and cell-surface receptor activation by endocrine or locally 
produced IGF1 and/or IGF2.
CONveRGeNCe OF TUMOR 
SUPPReSSOR p53 AND iGF1 
SiGNALiNG PATHwAYS
Early studies suggested a potential convergence of the p53 
and IGF1 signaling pathways (68). Binding of IGF1 to the 
IGF1R results in the recruitment and activation of PI3K to the 
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plasma membrane receptor and activation of the Akt protein 
kinase. Akt has several antiapoptotic substrates, such as BAD 
and Mdm2 (69). Akt is translocated to the cell nucleus where 
it phosphorylates forkhead transcription factors, leading to 
antiapoptotic signaling and cell growth (70). PI3K activity 
is counteracted by PTEN, a lipid phosphatase. PTEN func-
tions as a tumor suppressor and, similar to p53, is frequently 
mutated in breast cancer as well as other sporadic and familial 
malignancies (56). p53 regulates PTEN expression, while PTEN 
and inhibitors of Akt signaling upregulate p53 expression (71). 
As described below, the functional and physical connections 
between the IGF1 signaling pathways and tumor suppressor 
p53 take place at multiple levels of biological regulation (e.g., 
transcription, translation, stability, etc.) and occur in several 
cellular compartments (e.g., nucleus, cytoplasm).
The ubiquitin ligase Mdm2 is of primary importance in 
regulation of p53 activity (72), and IGF1 was shown to induce 
p53 degradation in an Mdm2-dependent manner (73). Girnita 
et al. have shown that Mdm2 physically associates with IGF1R 
and causes IGF1R ubiquitination and degradation (74). Mdm2 
serves as a ligase in ubiquitination of the IGF1R and thereby 
causes its degradation by the proteasome system. Consequently, 
by sequestering Mdm2 in the cell nuclei, the level of p53 may 
indirectly influence the expression of IGF1R. This function of 
Mdm2 and p53 constitutes a potential mechanism for the regula-
tion of IGF1R and cell growth. Various other mechanisms and 
signaling pathways have been suggested to participate in the 
convergent tasks of p53 and the IGF system and are thus regarded 
as potential therapeutic targets (75). This multifocal signal 
modulation therapy includes, in addition to the IGF1 axis and 
the Mdm2–p53 loop, additional targets, including the epidermal 
growth factor receptor, mammalian target of rapamycin, AR and 
ER, NFkB, etc.
An intact p53 signaling pathway is a critical prerequisite for 
many of the biological actions of IGF1. KLF6, a zinc-finger of 
the Krüppel-like family, was identified as a transcription factor 
involved in the regulation of genes associated with response to 
injury (76, 77). In addition, KLF6 plays a tumor suppressor role 
in colon and prostate cancer (78). IGF1 was shown to stimulate 
KLF6 gene transcription in cells with normal, but not disrupted, 
p53 (79). These results identify the KLF6 gene as a downstream 
target for IGF1 action and suggest that the mechanism of action 
of IGF1 requires an intact p53 pathway. An additional example 
of the critical need for p53 in IGF1 action is provided by folic 
acid, a member of the vitamin B family. Folic acid exhibits chemo-
preventive activity, and part of the antiproliferative action of this 
micronutrient can be attributed to its ability to inhibit IGF1R 
gene expression in a p53-dependent manner (80). The protective 
effect of folic acid was abrogated in cells lacking p53.
Of major interest, a recent study identified the GH gene as a 
direct transcriptional target of p53. Pituitary adenomas secreting 
GH are always benign and exhibit DNA damage and a senescent 
phenotype. The laboratory of Shlomo Melmed tested the effect 
of nutlin-induced p53-mediated senescence in pituitary cells 
(81). The authors showed that DNA damage induced by nutlin 
triggers the p53 senescent pathway, with subsequent induction 
of intracellular pituitary GH. In contrast, GH was not induced in 
p53-null cells. p53 was capable of binding specific GH promoter 
motifs and enhanced GH gene transcription and secretion in 
senescent pituitary adenoma cells. In summary, intracrine GH 
acts in pituitary cells as an apoptosis switch for p53-mediated 
senescence, likely protecting the pituitary adenoma from pro-
gression to malignancy. Given the key role of GH in regulation of 
IGF1 biosynthesis and secretion, the identification of the GH gene 
as a novel target for p53 action is consistent with the concept that 
the tumor suppressor constitutes an important systemic regulator 
of the entire GH–IGF1 endocrine axis.
iGF1, iGF1R, AND DNA DAMAGe
Evidence accumulated in recent years revealed a strong link 
between the IGF1R gene and radiosensitivity, defined as cell kill-
ing after exposure to ionizing radiation. IGF1R overexpression 
in fibroblasts conferred radioresistance and, conversely, addi-
tion of antisense oligomers against IGF1R mRNA reversed the 
radioresistant phenotype (82). Immunohistochemical analysis 
of primary breast tumors indicated that high levels of IGF1R cor-
related with ipsilateral tumor recurrence following lumpectomy 
and radiation therapy. Of interest, the only growth factor recep-
tor that provided protection from ultraviolet-induced apoptosis 
in keratinocytes was the IGF1R (83). It is conceivable that the 
activated IGF1R may, on one hand, function as a survival factor 
for irradiated cells and, on the other hand, induce a postmitotic 
state that prevents passage of damaged DNA to daughter cells.
The ATM (ataxia-telangiectasia mutated) gene encodes a 
350-kDa protein whose mutation in ataxia-telangiectasia, a genetic 
neurological disorder, leads to progressive neuronal degen-
eration, premature aging, immunological abnormalities, and an 
increased risk of cancer (84). The central role of the ATM protein 
in signaling DNA damage is now well established. Ionizing, but 
not ultraviolet, radiation enhances ATM kinase activity and phos-
phorylates a series of target proteins, including p53 and BRCA1, 
which, as described here, are involved in cell cycle control and 
repair of DNA damage (85). The potential role of the IGF1R gene 
as a target in an ATM-dependent pathway involved in regulating 
the radiation response was inferred from studies demonstrating 
that IGF1R levels were reduced in cells carrying mutations in the 
ATM gene (86).
Complementation of mutant cells with the ATM cDNA 
resulted in increased IGF1R promoter activity and elevated 
IGF1R levels (87). Furthermore, forced expression of the IGF1R 
in ataxia-telangiectasia cells conferred increased radioresistance. 
Hence, data indicate that the IGF1R gene is a novel downstream 
target in an ATM-mediated DNA damage response pathway. The 
fact that p53 has been characterized as a target for ATM action 
suggests that the regulation of IGF1R by ATM is, most probably, 
a p53-dependent process. Deregulated expression of the IGF1R 
gene after ionizing radiation is linked to genomic instability and 
increased cancer rates.
Finally, the laboratory of Valentine Macaulay has shown that 
downregulation of IGF1R in melanoma cells was associated 
with enhanced radiosensitivity (88). The authors also showed 
that IGF1R depletion delays repair of radiation-induced DNA 
double-strand breaks (DSB) and demonstrated that IGF1R affects 
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DSB repair by modulating both major DSB repair pathways, i.e., 
non-homologous end-joining and homologous recombination 
repair (20, 89, 90).
ReGULATiON OF THe iGF AXiS BY 
GeNOMe PROTeCTiON GeNeS: 
A COMMON THeMe iN CeLL BiOLOGY
The identification of the IGF1R gene as a downstream target for 
members of the p53 family of genome protection genes led us to 
postulate the hypothesis that the expression and activity of the 
IGF1 axis, in general, and the IGF1R in particular, is governed 
by multiple families of negative regulators, i.e., tumor suppressor 
genes (35, 44). The rationale for this hypothesis lies in the fact 
that the IGF1R is usually overexpressed in tumors displaying 
loss-of function mutations of tumor suppressor genes (7–9, 26). In 
other words, our model proposes that the IGF1R gene constitutes 
a common downstream target for multiple tumor suppressors. 
While tumor suppressors might differ in their organ-specific 
expression, mechanisms of activation, type of tumors involved, 
and other parameters, they share the IGF1R pathway as a shared 
response path.
The breast and ovarian cancer susceptibility gene (BRCA1) 
is a transcription factor with well-defined roles in DNA dam-
age repair, cell growth, and apoptosis (91, 92). Mutations in the 
BRCA1 gene are detected in a large proportion of families with 
inherited breast and/or ovarian cancer (93, 94). BRCA1 mutation 
carriers have up to 87% estimated cumulative risk of developing 
breast cancer by age 70. Consistent with its tumor suppressor role, 
forced expression of BRCA1 in breast cancer cells led to a marked 
reduction in endogenous IGF1R levels and promoter activity 
(95–97). In contrast, a mutant BRCA1 gene encoding a truncated 
version of the molecule (del185AG, a mutation with a high inci-
dence among Ashkenazi Jews) had no effect on IGF1R expression. 
These results are consistent with the above postulated hypothesis, 
which proposes that the IGF1R gene is a downstream target for 
BRCA1 (and other tumor suppressors) action. Activation of 
BRCA1 in response to DNA damage, oxidative stress, or other 
cellular insults, may lead to a reduction in IGF1R levels and IGF 
action (98). Mobility shift assays performed with the full-length, 
in vitro-translated, BRCA1 failed to reveal binding of the protein 
to IGF1R promoter sequences. However, BRCA1 was shown to 
bind zinc-finger protein Sp1, a potent IGF1R gene transactivator, 
hence preventing it from binding to the IGF1R promoter.
A manifestation of the mechanistic interplay between 
BRCA1/BRCA2 and the IGF axis is seen in the clinics. Immuno-
histochemical analysis of IGF1R levels in breast tumor specimens 
derived from BRCA1/BRCA2 mutation carriers, compared to 
matched sporadic breast cancer patients, revealed higher IGF1R 
levels in tumors of BRCA mutation carriers (99). Furthermore, 
evidence in support of a complex interplay between the IGF1 
axis and tumor suppressor BRCA1 was provided by studies 
showing that IGF1 increases BRCA1 gene expression and 
enhances BRCA1 promoter activity (100). Inhibitory control of 
IGF1R gene expression by BRCA1 may constitute a protection 
mechanism that prevents from normal breast cells from engaging 
in mitogenic activity. Lack of IGF1R inhibition by mutant BRCA1 
may lead to enhanced IGF1R levels, an important prerequisite 
for malignant transformation (101).
Additional examples of tumor suppressor genes whose mecha-
nisms of action involve transcriptional suppression of the IGF1R 
gene are the von-Hippel–Lindau (VHL) protein, a gene with 
important roles in the etiology of renal cancer (102), and WT1, a 
zinc-finger tumor suppressor with key roles in Wilm’s tumor, or 
nephroblastoma (103, 104). Of cardinal importance, the ability 
of WT1 to suppress IGF1R transcription is strictly dependent on 
the cellular status of p53. Thus, WT1 exerts its inhibitory role only 
in cells expressing a wild-type p53 gene, whereas it is unable to 
repress the IGF1R gene in cells with a mutant p53.
In summary, the IGF1R gene constitutes a common target 
for multiple oncogenes and antioncogenes. Inhibition of IGF1R 
expression and activation by negative growth regulators is 
expected to keep IGF1R levels below a certain threshold. We 
assume that low IGF1R levels are, for the most part, incompatible 
with the execution of mitogenic activities (Figure 3). p53 displays 
both direct and indirect roles in regulation of the IGF1R gene by 
virtue of its capacity to modulate the transcriptional activities of 
multiple transcription factors.
CAN p53 STATUS PReDiCT 
ReSPONSiveNeSS TO iGF1R-DiReCTeD 
TARGeTeD THeRAPieS?
Given its strong pro-survival activity along with its universal 
expression in cancer cells, the IGF1R emerged in recent years 
as a promising therapeutic target in oncology (105–107). 
Unfortunately, results of phase I/II clinical trials have shown vari-
able responses to IGF1R-directed therapies. The reasons for the 
failure to translate solid experimental and preclinical data into the 
clinics are complex and not fully explored. However, it has been 
suggested that most clinical trials using IGF1R inhibitors were 
conducted on unselected patients, and this fact had a negative 
impact on trials outcome. Therefore, identification of biomarkers 
that can predict response to targeted therapy is a major goal in 
current cancer treatment (108, 109).
While in certain cancers, including Ewing’s and rhabdomyo-
sarcoma, tumor IGF1R levels were correlated with responsiveness 
to IGF1R-directed therapies, most clinical data seem to indicate 
that IGF1R expression levels, per se, do not predict sensitivity to 
IGF1R inhibition (110). Among a number of potential scenarios, 
it has been suggested that the specific molecular context and the 
complexity of the IGF1R–INSR hybrid receptors formation may 
explain part of the contradictory results. Likewise, circulating 
ligand and/or IGFBP levels are not always associated with 
the degree of anti-IGF1R effectiveness. Regarding the impact 
of IGF1R subcellular distribution on tumor phenotype and 
responsiveness to IGF1R-directed therapies, Aleksic et al. (111) 
reported the presence of nuclear IGF1R in primary renal cancer 
cells, formalin-fixed tumors, preinvasive lesions of the breast, 
and rapidly proliferating non-malignant tissues, and they also 
demonstrated that nuclear IGF1R was associated with poor 
prognosis in renal cancer. Asmane et  al. (112) performed an 
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immunohistochemical analysis of nuclear IGF1R in patients with 
unresectable or metastatic soft tissue sarcomas, Ewing’s sarcoma, 
and osteosarcoma treated with anti-IGF1R. In contrast to the 
previous study, exclusive intranuclear IGF1R presence was cor-
related with a better progression-free survival. Further studies are 
expected to shed light on this emerging aspect of IGF1R biology.
The impact of p53 mutational status on selective IGF1R-
targeted therapies is of major translational relevance. A recent 
study has shown that picropodophyllin, an IGF1R inhibitor of 
the cyclolignan family, prevented the growth of wild-type, but 
not mutant, p53-expressing colorectal carcinoma cell lines (113). 
Likewise, cixutumumab, an IGF1R monoclonal antibody, inhib-
ited proliferation of a uterine papillary serous carcinoma cell line 
expressing a wild-type p53 gene but had no effect on uterine cells 
containing a mutant p53 (114). In conclusion, the potential role of 
p53 as a biomarker for IGF1R-directed therapies in human can-
cers must be confirmed by large cell-based and patients’ analyses.
Finally, a number of obstacles must be resolved in order to 
translate the success of preclinical studies into the clinical setting. 
These difficulties are primarily due to the considerable similarity 
between the mature forms of IGF1R and INSR. The homology 
between the tyrosine kinase domains of both receptors reaches 
84%, and the downstream pathways elicited by IGF1R and INSR 
are almost identical (14). The possible effect of IGF1R-targeted 
therapy on INSR action is of major concern. Impaired insulin 
signaling in classical insulin target organs (e.g., muscle, adipose 
tissue, etc.) may lead to metabolic complications, including 
development of insulin resistance. On the other hand and given 
the well-documented involvement of INSR in various types of 
cancer, in particular breast tumors, experts in the field advise the 
combined targeting of both IGF1R and INSR.
iGF1 AND p53 COLLABORATe iN 
ReGULATiON OF MeTABOLiSM
In addition to the well-established interplay between the IGF1 
and p53 signaling pathways in the context of cell survival, pro-
liferation, and cancer, as described above, evidence is mounting 
in support of novel homeostatic and metabolic activities of p53. 
Since its discovery in the mid-1950s, the insulin-like activities of 
IGF1 have been particularly well described. IGF1 has direct effects 
on fuel metabolism and, when given acutely, it enhances glucose 
uptake by muscle and abrogates hepatic glucose production (1). 
p53 has an important role in promoting oxidative phospho-
rylation (115). In addition, p53 has been shown to contribute to 
mitochondrial mass, a parameter of energetic expenditure (116), 
and cells expressing the tumor suppressor were shown to derive 
a larger portion of their ATP from oxidative phosphorylation, 
in comparison to cells devoid of p53 (117). Further evidence of 
p53 involvement in energy balance arises from the observation 
that, in addition to its nuclear localization, p53 is also present in 
mitochondria (118). It has been suggested that the mitochondrial 
presence of p53 in resting cells attests to the involvement of the 
tumor suppressor in normal mitochondrial activity.
p53 has an important role in the regulation of glycolysis. Most 
experimental evidence seems to indicate that, in agreement with 
its tumor suppressor role, p53 is capable of lowering glycolysis 
(119, 120). This activity can be regarded as an attempt by p53 to 
counter the acquisition of aerobic glycolysis usually associated 
with cancer cells (115). However, this intuitive rationalization 
is obscured by the finding that enhancement of glycolysis has 
also been associated, under certain circumstances, with p53 
action. Of major interest, p53 has been identified as an important 
regulator of glucose transport, and wild-type p53 was shown to 
repress transcription of both GLUT1 and GLUT4 promoters in 
transfection assays (32). The inhibitory effect of wild-type p53 
was abolished when cells were transfected with tumor-derived 
mutant versions of p53, harboring mutations in codons 143, 248, 
or 273. Evidence in support of a direct effect of p53 was provided 
by results of mobility shift assays showing binding of p53 to 
GLUT4 promoter sequences. These results suggest that the ability 
of p53 to prevent tumor initiation is, in part, mediated by its abil-
ity to inhibit glucose uptake and cell energy supply. In contrast, 
mutant p53s have an impaired capacity to repress GLUT1 and 
GLUT4 promoters. Of interest, p53 was also shown to promote 
the expression of gluconeogenesis-related genes (e.g., G6PC, 
PCK2, etc.) and to enhance hepatic glucose production (121). By 
facilitating glucose export, p53 may prevent it from being shunted 
to proliferative pathways, such as glycolysis.
In the context of lipid metabolism, both IGF1 and p53 
have been linked to sterol regulatory element binding protein 
(SREBP) activity. SREBPs are transcription factors that bind to 
sterol regulatory element DNA sequences, leading to enhanced 
synthesis of enzymes involved in sterol biosynthesis. SREBPs 
are required for cholesterol and fatty acid biosynthesis. p53 was 
shown to be induced in adipocytes of ob/ob mice, leading to inhi-
bition of SREBP-1 and lipogenic genes (122). Luciferase assays 
revealed that p53 expression suppressed the promoter activity 
of the SREBP-1c gene. Hence, p53 activation may constitute a 
negative feedback loop with important roles in prevention of fat 
accumulation in adipocytes. On the other hand, IGF1 was shown 
to stimulate SREBP expression and lipogenesis via activation of 
the PI3K pathway (123). Taken together, the interplay between 
the IGF1 and p53 pathways may have major implications in lipid 
metabolism and, probably, obesity.
CONCLUDiNG ReMARKS
Overexpression of the IGF1R gene constitutes a common trait 
of many, if not most, tumors. The expression of the IGF1R gene 
is determined, to a large extent, at the transcriptional level, and 
the IGF1R promoter has been identified as a molecular target to 
a family of stimulatory transcription factors as well as nuclear 
proteins with tumor suppressor activity. Tumor suppressor p53 
is the most frequently mutated molecule in human cancer. p53 
is capable of arresting cell cycle progression at the G1 phase, 
thus enabling damaged DNA to be repaired before the repli-
cative phase of the cell cycle. Alternatively, p53 can elicit an 
apoptotic program. In the present review article, we provided 
evidence that the mechanisms of action of wild-type p53 and 
p53 homologs (e.g., p63, p73) involve transcriptional suppres-
sion of the IGF1R gene. Gain-of-function or loss-of-function 
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mutations of p53 disrupt its inhibitory activity and generate 
potentially oncogenic molecules capable of transactivating the 
IGF1R gene. While the interplay between the IGF1 signaling axis 
and the p53 genome protection pathways has been primarily 
investigated in the context of cancer cells, new evidence links 
these converging networks to the regulation of metabolism, 
including glucose transport, glycolysis, mitochondrial biology, 
and energy generation. Dissection of these complex regulatory 
loops will have a major impact on our comprehension of basic 
physiopathological processes as well as on our ability to person-
alize cancer therapies.
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